Study on genetic factors in familial prostate cancer
ProGene: Etude Genetique et Epidemiologique du Cancer de la Prostate Familial
Centre de Recherche sur les Pathologies Prostatiques · NCT01221168
This study is trying to find out how genetics affect prostate cancer in men with a family history of the disease to improve screening and treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre de Recherche sur les Pathologies Prostatiques (other) |
| Drugs / interventions | radiation |
| Locations | 5 sites (Angers and 4 other locations) |
| Trial ID | NCT01221168 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify genetic and molecular factors that influence the natural history of prostate cancer and its treatment responses. It focuses on both constitutional genetic alterations in men with a family history of prostate cancer and somatic mutations that contribute to disease aggressiveness. The study will establish a registry that includes biological samples from men with confirmed prostate cancer and healthy controls, allowing for comparative analysis. The ultimate goal is to enhance screening and therapeutic management of prostate cancer based on genetic insights.
Who should consider this trial
Good fit: Ideal candidates include men with histologically confirmed prostate cancer, those from hereditary prostate cancer families, and healthy men without prostate cancer.
Not a fit: Patients who do not have a family history of prostate cancer or those who refuse to participate will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved screening and treatment strategies for prostate cancer based on genetic susceptibility.
How similar studies have performed: Other studies have shown success in identifying genetic factors related to prostate cancer, indicating that this approach is promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patient with a histological confirmed prostate cancer * member of a hereditary prostate cancer family * healthy control men without prostate cancer Exclusion Criteria: * Absence of signed informed consent * refusal to participate in the study
Where this trial is running
Angers and 4 other locations
- Department of Urology, CHU Angers — Angers, France (RECRUITING)
- Department of Urology, Hopital de la Cavale Blanche — Brest, France (RECRUITING)
- Department of Urology, CHU Dijon — Dijon, France (RECRUITING)
- Department of Urology, Hopital Pitié-Salpetriere — Paris, France (RECRUITING)
- Department of Urology, Hopital Tenon — Paris, France (COMPLETED)
Study contacts
- Principal investigator: Olivier Cussenot, MD, Ph.D. — Centre de Recherche sur les Pathologies Prostatiques
- Study coordinator: Olivier Cussenot, MD, PhD
- Email: olivier.cussenot@cerepp.org
- Phone: 00 33 1 56 01 76 46
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Prostate Cancer, prostate, cancer, genetic, epidemiology, susceptibility